ABUS
Price
$3.23
Change
-$0.23 (-6.65%)
Updated
Dec 18, 04:05 PM (EDT)
71 days until earnings call
ROIV
Price
$11.81
Change
-$0.34 (-2.80%)
Updated
Dec 18, 04:30 PM (EDT)
61 days until earnings call
Ad is loading...

ABUS vs ROIV

Header iconABUS vs ROIV Comparison
Open Charts ABUS vs ROIVBanner chart's image
Arbutus Biopharma
Price$3.23
Change-$0.23 (-6.65%)
Volume$100
CapitalizationN/A
Roivant Sciences
Price$11.81
Change-$0.34 (-2.80%)
Volume$14.2K
CapitalizationN/A
ABUS vs ROIV Comparison Chart
Loading...
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ROIV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABUS vs. ROIV commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a Hold and ROIV is a StrongBuy.

COMPARISON
Comparison
Dec 18, 2024
Stock price -- (ABUS: $3.46 vs. ROIV: $12.15)
Brand notoriety: ABUS and ROIV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABUS: 136% vs. ROIV: 88%
Market capitalization -- ABUS: $655.64M vs. ROIV: $8.84B
ABUS [@Biotechnology] is valued at $655.64M. ROIV’s [@Biotechnology] market capitalization is $8.84B. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 0 FA rating(s) are green whileROIV’s FA Score has 1 green FA rating(s).

  • ABUS’s FA Score: 0 green, 5 red.
  • ROIV’s FA Score: 1 green, 4 red.
According to our system of comparison, ROIV is a better buy in the long-term than ABUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 4 TA indicator(s) are bullish while ROIV’s TA Score has 6 bullish TA indicator(s).

  • ABUS’s TA Score: 4 bullish, 4 bearish.
  • ROIV’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, ROIV is a better buy in the short-term than ABUS.

Price Growth

ABUS (@Biotechnology) experienced а -7.98% price change this week, while ROIV (@Biotechnology) price change was +0.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.65%. For the same industry, the average monthly price growth was +1.44%, and the average quarterly price growth was +4.25%.

Reported Earning Dates

ABUS is expected to report earnings on Feb 27, 2025.

ROIV is expected to report earnings on Feb 17, 2025.

Industries' Descriptions

@Biotechnology (-3.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ROIV($8.85B) has a higher market cap than ABUS($656M). ABUS YTD gains are higher at: 38.400 vs. ROIV (8.192). ROIV has higher annual earnings (EBITDA): 4.15B vs. ABUS (-75.14M). ROIV has more cash in the bank: 5.39B vs. ABUS (128M). ABUS has less debt than ROIV: ABUS (1.45M) vs ROIV (52.7M). ROIV has higher revenues than ABUS: ROIV (129M) vs ABUS (6.74M).
ABUSROIVABUS / ROIV
Capitalization656M8.85B7%
EBITDA-75.14M4.15B-2%
Gain YTD38.4008.192469%
P/E RatioN/A2.19-
Revenue6.74M129M5%
Total Cash128M5.39B2%
Total Debt1.45M52.7M3%
FUNDAMENTALS RATINGS
ABUS: Fundamental Ratings
ABUS
OUTLOOK RATING
1..100
6
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
PROFIT vs RISK RATING
1..100
59
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
49
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABUSROIV
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
63%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
65%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
64%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
65%
Advances
ODDS (%)
Bullish Trend 27 days ago
80%
Bullish Trend 2 days ago
72%
Declines
ODDS (%)
Bearish Trend 6 days ago
79%
Bearish Trend 6 days ago
73%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
64%
Aroon
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 3 days ago
70%
View a ticker or compare two or three
Ad is loading...
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ROIV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
QTJA25.060.03
+0.14%
Innovator Growth Accelerated Pls ETF Jan
SUSB24.80-0.02
-0.08%
iShares ESG 1-5 Year USD Corp Bd ETF
EMXC57.03-0.58
-1.01%
iShares MSCI Emerging Mkts ex China ETF
SHOC47.49-0.65
-1.35%
Strive U.S. Semiconductor ETF
TSME38.33-0.58
-1.49%
Thrivent Small-Mid Cap ESG ETF

ABUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with ARRY. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then ARRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABUS
1D Price
Change %
ABUS100%
-2.54%
ARRY - ABUS
43%
Loosely correlated
+6.01%
AXON - ABUS
42%
Loosely correlated
-2.09%
ROIV - ABUS
39%
Loosely correlated
+0.41%
VCYT - ABUS
38%
Loosely correlated
-2.52%
THRD - ABUS
38%
Loosely correlated
+2.07%
More

ROIV and

Correlation & Price change

A.I.dvisor indicates that over the last year, ROIV has been loosely correlated with IMVT. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ROIV jumps, then IMVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ROIV
1D Price
Change %
ROIV100%
+0.41%
IMVT - ROIV
57%
Loosely correlated
+1.01%
ARGX - ROIV
46%
Loosely correlated
+0.90%
AXON - ROIV
43%
Loosely correlated
-2.09%
RARE - ROIV
41%
Loosely correlated
-0.99%
PGEN - ROIV
41%
Loosely correlated
+2.46%
More